Hepatology

Hosts discuss a consensus repot from the ADA focused on screening and early interview of MASLD in people with diabetes.

Hosts Kimberly Brown and Nancy Reau break down 4 of the top abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress.

Gyre Therapeutics plans to file an NDA in China based on the phase 3 CHB data and, pending IND clearance, is looking to initiate a phase 2 MASH fibrosis trial in the US.

Stoller describes the potential of a novel AI model to help address AATD underrecognition, citing findings from his research on its performance in a Cleveland Clinic cohort.

Banerjee describes the value of multiorgan MRI for predicting cardiac and liver outcomes and cT1’s prognostic utility in liver disease.

Levy explains the unmet need for effective PSC treatment options and reviews new data from the phase 2 ELMWOOD trial of elafibranor in PSC.

The Amsterdam-Oxford Model successfully predicted adverse outcomes in a US cohort of PSC patients, validating its generalizability.

Use of efruxifermin did not result in a significant reduction in fibrosis without worsening of MASH at week 36 compared with placebo in the phase 2b SYMMETRY trial.

Findings suggest sleep disorders are common in PBC and are linked to worse biochemical markers, greater symptom burden, and reduced treatment response rates.

Najy Issa, MD, describes “underwhelming” universal HBV screening uptake since 2023 CDC guidelines were implemented and steps to get more patients screened.

Mazen Noureddin, MD, MHSc, reviews findings from a phase 2 study of efimosfermin alfa (BOS-580) for F2/F3 fibrosis due to MASH.

Findings from a posthoc analysis of 2 phase 3 trials suggest seladelpar monotherapy has similar safety and efficacy to seladelpar combined with UDCA.

Zhang describes the importance of multidisciplinary care for preventing alcohol relapse post-transplant, citing success from Mass General’s LIFT Clinic.

FibroX showed superior performance, interpretability, and potential cost savings relative to FIB-4, improving risk stratification and management in MASLD.

The month in review spotlights hepatic FDA and pipeline news as well as new research on alcohol and obesity's impact on liver health and PBC.

Liver Lineup: Updates & Unfiltered Insights is a hepatology podcast from HCPLive hosted by Nancy Reau, MD, and Kimberly Brown, MD, exploring the latest news and research in liver disease.

In this episode, hosts explore the promise of semaglutide 2.4 mg in improving liver outcomes for MASH in the Phase 3 ESSENCE trial.

New Phase 3 trial results reveal semaglutide's effectiveness in treating metabolic dysfunction-associated steatohepatitis, offering hope for millions.

Findings suggest the benefit of MASLD-focused anti-inflammatory interventions for promoting brain health and preventing accelerated brain aging.

Findings suggest greater physical activity volume and intensity are linked to a reduced risk of all-cause and cardiovascular disease mortality in MASLD.

Findings suggest frequent consumption of non-skimmed milk may heighten the risk of developing MAFLD.

1 in 5 patients were incompletely screened for CFLD based on 2023 guidelines, with Hispanic ethnicity and public insurance linked to an increased risk.

Study findings highlight regional variability in the prevalence of PBC in the US in 2021, additionally suggesting potential barriers to specialist care.

Class 3 obesity conferred the greatest risk of mortality, complications, and higher resource utilization in alcohol-associated hepatitis hospitalizations.

Meta-analysis results showed patients with ZZ AATD had a greater risk of liver disease and liver cancer than patients in comparator cohorts.